The DOI matches its Crossref record.
Entry Decisions in the Generic Pharmaceutical Industry
Open accessAbstract
Data on all generic drug entries in the period 1984-1994 are used to estimate which markets heterogeneous potential entrants will decide to enter. I find that organizational experience predicts entry. Firms tend to enter markets with supply and demand characteristics similar to the firm's existing drugs. Larger revenue markets, markets with more hospital sales, and products that treat chronic conditions attract more entry. The simultaneous nature of entry leads to an additional interpretation: specialization is profitable because of the severe risk to profits when a market is "overentered." However, I am unable to make any conclusions about the efficiency of entry decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The birth of capabilities: market entry and the importance of pre-history
Helfat, C. E. (2002) · Industrial and Corporate Change · doi:10.1093/icc/11.4.725 · Cited by 1,087
Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry
Acemoglu, D., & Linn, J. (2004) · The Quarterly Journal of Economics · doi:10.1162/0033553041502144 · Cited by 967
Reflections on “Profiting from Innovation”
Teece, D. J. (2006) · Research Policy · doi:10.1016/j.respol.2006.09.009 · Cited by 733
The development of the resource‐based view of the firm: A critical appraisal
Lockett, A., Thompson, S., & Morgenstern, U. (2009) · International Journal of Management Reviews · doi:10.1111/j.1468-2370.2008.00252.x · Cited by 680
Nerkar, A., & Roberts, P. W. (2004) · Strategic Management Journal · doi:10.1002/smj.417 · Cited by 481
Metadata
- Authors
- Morton, F. M. S.
- Venue
- National Bureau of Economic Research
- Publisher
- National Bureau of Economic Research
- Published
- 1997-09
- Volume
- 30
- Issue
- 3
- Pages
- 421-40
- OpenAlex
- W3121488608
- Cited by
- 170
- References
- 0
- Type
- report
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Entry Decisions in the Generic Pharmaceutical Industry. https://app.cochat.ai/papers/10.3386/w6190
- The paper
- Morton, F. M. S. (1997). Entry Decisions in the Generic Pharmaceutical Industry. National Bureau of Economic Research. https://doi.org/10.3386/w6190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.